Health
FDA grants rare disease designations to investigational brain tumor drug – News-Medical.Net
The U.S. Food and Drug Administration has awarded Rare Pediatric Disease Designation (RPDD) for diffuse intrinsic pontine glioma (DIPG) and Orphan Drug Designation for treatment of malignant glioma to OKN-007, an investigational drug discovered at the Oklahom…
Reviewed by Emily Henderson, B.Sc.Sep 2 2020
The U.S. Food and Drug Administration has awarded Rare Pediatric Disease Designation (RPDD) for diffuse intrinsic pontine glioma (DIPG) and Orphan Drug Designation for treatment of malignant glioma to OKN-007, an investigational drug discovered at the Oklahoma Medical Research Foundation and being developed by Oblato, Inc.
DIPG is a fast-growing pediatric cancer that starts in the brain stem. It is one of several sub-categories of malignant gliomas,…
-
Business10 hours agoCould a small investor today match the historic returns of Warren Buffett?
-
Noosa News23 hours agoBasic cyber steps can block most attacks – Proctor
-
Noosa News18 hours agoWhat instrument did Japan’s heavy-metal PM play? Take the Brisbane Times Quiz
-
Business23 hours agoAfter topping estimates in September, are Magellan shares now a buy?